Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Paris  >  Valneva    VLA   FR0004056851

VALNEVA (VLA)
Mes dernières consult.
Most popular
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

VIVALIS : MISE A DISPOSITION DU DOCUMENT DE REFERENCE 2011

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/27/2012 | 07:35am CEST

VIVALIS PUBLIE SON
DOCUMENT DE REFERENCE 2011

Nantes, Lyon (France) - 27 avril 2012 : VIVALIS (NYSE Euronext Paris : VLS), société biopharmaceutique, annonce que son Document de référence 2011 a été déposé le 25 avril 2012 auprès de l'Autorité des Marchés Financiers (AMF) sous le numéro D12-0412.

Des exemplaires du présent Document de Référence sont disponibles sans frais auprès de la Société, au 6, rue Alain Bombard, 44821 Saint-Herblain cedex, ainsi qu'en version électronique sur le site internet de la Société (www.vivalis.com) et  sur le site internet de l'Autorité des marchés financiers (www.amf-france.org:
http://www.amf-france.org/).

Les documents suivants sont notamment intégrés dans le document de référence 2011 :
-       le rapport financier annuel,
-       le rapport du Président du Conseil de surveillance sur les conditions d'organisation et de préparation des travaux du Conseil de surveillance et sur les procédures de contrôle interne mises en place par la Société,
-       les informations relatives aux honoraires versés aux commissaires aux comptes,
-       le document d'information annuel.

VIVALIS MISE A DISPOSITION DU DOCUMENT DE REFERENCE:
http://hugin.info/143334/R/1606613/509370.pdf



This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.

Source: VIVALIS via Thomson Reuters ONE

HUG#1606613
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on VALNEVA
10/13 ZIKA VIRUS VACCINES MARKET : Top Company Profile, Clinical Trials, Regulatory La..
08/31 VALNEVA : Reports Robust H1 2017 Financial Results & Major R&D Progress Company ..
08/31 VALNEVA : Reports Robust H1 2017 Financial Results & Major R&D Progress
08/01 VALNEVA : Announces Expansion of its Management Board - Strengthening Senior Man..
08/01 VALNEVA : Announces Expansion of its Management Board - Strengthening Senior Man..
07/27 VALNEVA : and Emergent BioSolutions Join Forces to Develop a Vaccine against the..
07/27 EMERGENT BIOSOLUTIONS : Secures Exclusive Worldwide Rights to Valnevas Zika Vacc..
07/26 VALNEVA : and Emergent BioSolutions Join Forces to Develop a Vaccine against the..
07/24 VALNEVA : Receives FDA Fast Track Designation for its Lyme Disease Vaccine Candi..
06/30 VALNEVA : Announces Successful Outcome of its AGM and the Appointment of two new..
More news
News from SeekingAlpha
09/01 Valneva's (INRLF) CEO Thomas Lingelbach on Q2 2017 Results - Earnings Call Tr..
08/31 Valneva SE 2017 Q2 - Results - Earnings Call Slides
08/31 Valneva SE reports Q2 results
06/09 Valneva SE (INRLF) Presents At Jefferies 2017 Global Healthcare Conference - ..
Financials (€)
Sales 2017 108 M
EBIT 2017 -0,77 M
Net income 2017 -9,05 M
Debt 2017 41,7 M
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales 2017 2,33x
EV / Sales 2018 2,03x
Capitalization 211 M
Chart VALNEVA
Duration : Period :
Valneva Technical Analysis Chart | VLA | FR0004056851 | 4-Traders
Technical analysis trends VALNEVA
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Average target price 4,19 €
Spread / Average Target 54%
EPS Revisions
Managers
NameTitle
Thomas Lingelbach Co-President & Chief Executive Officer
Franck Grimaud Co-President & Chief Business Officer
Frédéric Grimaud Chairman-Supervisory Board
David Lawrence Chief Financial Officer
Klaus Schwamborn Vice President-Discovery Research & Innovation
Sector and Competitors
1st jan.Capitalization (M$)
VALNEVA-10.03%249
INCYTE CORPORATION13.96%24 054
QUINTILES IMS HOLDINGS INC35.48%22 162
LONZA GROUP59.15%19 392
CELLTRION, INC.--.--%19 297
ALNYLAM PHARMACEUTICALS, INC.206.36%10 522